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Abstract
Aim: Glucagon-like peptide-1 receptor agonist (GLP-1RA) and insulin combination
therapy is an effective treatment option for type 2 diabetes, but long-term data are
lacking. The aim was to assess the long-term efficacy of the GLP-1RA liraglutide in
subgroups by insulin use in the LEADER trial.
Materials and Methods: LEADER assessed cardiovascular (CV) safety and efficacy of
liraglutide (1.8 mg) versus placebo (plus standard of care therapy) in 9340 patients
with type 2 diabetes and high risk of CV disease, for up to 5 years. We analyzed CV
events, metabolic parameters and hypoglycaemia post hoc in three subgroups by
baseline insulin use (basal-only insulin, other insulin or no insulin). Insulin was a non-
random treatment allocation as part of standard of care therapy.
Results: At baseline, 5171 (55%) patients were not receiving insulin, 3159 (34%) were
receiving basal-only insulin and 1010 (11%) other insulins. Insulin users had a longer
diabetes duration and slightly worse glycaemic control (HbA1c) than the no-insulin
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subgroup. Liraglutide reduced HbA1c and weight versus placebo in all three sub-
groups (P < .001), and severe hypoglycaemia rate in the basal-only insulin subgroup.
The need for insulin was less with liraglutide. CV risk reduction with liraglutide was
similar to the main trial results in the basal-only and no-insulin subgroups.
Conclusions: In patients on insulin, liraglutide improved glycaemic control, weight
and need for insulin versus placebo, for at least 36 months with no increased risk of
severe hypoglycaemia, while maintaining CV safety/efficacy, supporting the combina-
tion of liraglutide and insulin for management of type 2 diabetes.
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1 | INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are recommended
for treatment of patients with type 2 diabetes in combination with met-
formin and other oral glucose-lowering drugs, as monotherapy for
patients not suited to metformin or in combination with insulin.1 Combin-
ing GLP-1RAs and insulin has complementary benefits on glycaemic con-
trol, while limiting insulin-induced weight gain and reducing
hypoglycaemia risk.2,3 Specifically, the addition of the GLP-1RA liraglutide
to basal insulin has been shown to improve glycaemic control and reduce
weight.4 Compared with the addition of bolus insulin, liraglutide reduces
weight and rates of hypoglycaemia.5,6 These findings are reflected in cur-
rent guidelines supporting the use of GLP-1RAs in combination with basal
insulin when glycaemic control is insufficient.1 However, long-term data
for GLP-1RA and insulin combination therapy regarding safety and effi-
cacy are lacking, as relevant clinical trials have generally been limited to a
maximum of 52 weeks' duration.3
The LEADER (ClinicalTrials.gov, NCT01179048) cardiovascular
(CV) outcomes trial compared the CV safety of liraglutide with placebo
when added to standard of care (including insulin) over a follow-up
period of up to 5 years (median 3.8 years).7 The main finding from this
trial was a reduced risk of major adverse CV events (MACE), along with
improvements in glycaemic control, body weight and systolic blood pres-
sure, and reduced rates of hypoglycaemia versus placebo.7 As a large
number of LEADER participants were on insulin, we assessed these out-
comes in patients by insulin use (basal-only insulin, other insulin or no
insulin) at baseline. In addition, we report changes in low-density lipopro-
tein cholesterol (LDL-C) and changes in need for insulin (initiation, inten-
sification, dose and discontinuation) during the trial in each treatment
group. This post hoc subgroup analysis provides long-term safety and
efficacy data for GLP-1RA and insulin combination therapy.
2 | MATERIALS AND METHODS
2.1 | Design
Detailed descriptions of the LEADER trial have been published previ-
ously.7,8 In brief, LEADER was a multinational (32 countries), double-
blind, randomized, placebo-controlled trial designed to assess the CV
safety and efficacy of liraglutide.7
Patients with type 2 diabetes were eligible for inclusion if they
had HbA1c > 7% (>53 mmol/mol), were at high risk of CV disease
(aged ≥50 years with established CV disease [CVD] or chronic kidney
disease, or aged ≥60 years with ≥1 risk factor for CVD) and were
treated with oral glucose-lowering drugs, insulin (human neutral prot-
amine Hagedorn, long-acting analog or premix insulin), a combination
of these, or were treatment-naïve at baseline.7 The use of GLP-1RAs,
dipeptidyl peptidase-4 inhibitors (DPP-4is), pramlintide or rapid-acting
insulin was an exclusion criterion.7
Patients were randomized 1:1 to liraglutide (up to 1.8 mg, as toler-
ated) or placebo, in addition to standard of care treatment, and
followed for a minimum of 3.5 years, and up to 5 years.7 Standard of
care treatment guidelines were followed that encouraged investiga-
tors to intensify treatment for patients who did not achieve
HbA1c ≤7.0% (53 mmol/mol), or their individualized glycaemic tar-
gets. The addition of any glucose-lowering therapy (including insulin)
was permitted, except for GLP-1RAs, DPP-4is or pramlintide.7
2.2 | Endpoints
The primary endpoint was the time to first occurrence of a composite
CV outcome comprising CV death, non-fatal myocardial infarction or
non-fatal stroke (MACE).7 Other endpoints assessed included metabolic
parameters such as HbA1c, body weight, systolic blood pressure and
LDL-C, and the occurrence of severe hypoglycaemia (hypoglycaemia
requiring the assistance of another person to administer carbohydrate,
glucagon or other resuscitative actions).7,9
2.3 | Statistical analysis
In this paper, we present the results from post hoc subgroup analyses
by insulin use at baseline. The primary analysis was performed for
MACE, HbA1c, body weight, systolic blood pressure, LDL-C, severe
hypoglycaemia and changes in insulin use (insulin initiation, basal insu-
lin intensification, insulin discontinuation and insulin dose), based on
three categories of insulin use at baseline: (a) basal-only insulin
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(intermediate or long-acting insulin only, ATC codes A10AE or
A10AC), (b) other insulin, basal insulin in combination with other insu-
lin or other insulin regimens (ATC codes A10AD [premixed prepara-
tions], A10AB [short-acting insulin] or codes starting A10A not
categorized elsewhere), and (c) no insulin.
Changes in HbA1c, insulin dose, body weight, systolic blood pres-
sure and LDL-C from baseline to 36 months were estimated using a
mixed model for repeated measurements with a compound symmetry
variance, with treatment, sex, region and insulin subgroup as fixed
effects, including the treatment and insulin subgroup interaction, and
with the baseline value of the variable being estimated (e.g. baseline
HbA1c for changes in HbA1c) and age as covariates, all nested within
the visit. Analyses of insulin dose were restricted to patients for
whom insulin dose data were available and reported in international
units (IU). The 36-month time point was used because it represents
the last scheduled clinic visit for the whole trial population at which all
of the parameters of interest were measured.
Rates of severe hypoglycaemia were compared using a negative
binomial regression model with treatment, sex, region and insulin sub-
group as fixed effects, treatment and insulin subgroup interaction and
age as covariates, and a log link and logarithm of the observation time
as offset.
A Cox proportional-hazards model with treatment group
(liraglutide or placebo) as a fixed factor was used to analyze time to
insulin initiation in patients not using insulin at baseline, and time to
intensification of basal insulin (addition of fast-acting insulin or change
to mixed insulin) in patients using basal insulin only at baseline. The
same model, but with addition of the insulin subgroup and the interac-
tion between randomized treatment group and insulin subgroup as
fixed factors, was used to analyze time to permanent discontinuation
of insulin during the trial in patients using insulin at baseline. The
numbers needed to treat (NNT) were calculated for avoiding insulin
initiation and obtaining permanent discontinuation of insulin during
the trial, respectively, according to the methods described by Altman
and Andersen.10
A Cox proportional-hazards model with treatment, subgroup, and
the interaction between treatment and subgroup as covariates was
used to analyze time to first MACE with liraglutide versus placebo in
the aforementioned three categories of baseline insulin use. The fol-
lowing analyses were also performed for MACE: (a) according to two
categories of insulin use at baseline (no insulin or any insulin), (b) by
three groups of total daily insulin dose at baseline (<30; ≥30 to <50;
and ≥ 50 IU), and (c) in patients not using insulin at baseline or during
the trial (i.e. censoring those who initiated insulin before first MACE,
at the time of insulin initiation).
3 | RESULTS
In the LEADER trial, 9340 patients with type 2 diabetes at high risk of
CV events were randomized to liraglutide (n = 4668) or placebo
(n = 4672), both in addition to standard of care therapy.7 Median
exposure to study drug (liraglutide or placebo) was 3.5 years, and the
median follow-up was 3.8 years.7
At baseline, 4169 (45%) patients were on insulin therapy. Of these
patients, 3159 (76%) were receiving basal only and 1010 (24%) were
treated with other insulin regimens, mostly premixed preparations
(908 patients).
Insulin users (basal-only and other insulin subgroups) in both ran-
domized treatment groups had a longer duration of diabetes, slightly
worse glycaemic control (HbA1c) and more frequently had established
heart disease and chronic kidney disease than patients not using insu-
lin at baseline (Table 1). Baseline characteristics and demographics
were balanced between randomized treatment groups (liraglutide and
placebo) in the three subgroups by insulin use (data not shown).
In patients on insulin, the HbA1c reductions in response to
liraglutide during the trial were similar to those not on insulin (Figure 1,
Table 2). Compared with the placebo-treatment group, greater propor-
tions of patients in the liraglutide-treatment group achieved
HbA1c <7.0% (<53 mmol/mol), <7.5% (<58 mmol/mol) or <8.0%
(<64 mmol/mol), as well as clinically relevant reductions in HbA1c
(>0.5% [>5 mmol/mol]) without weight gain at 36 months, in all three
subgroups by insulin use at baseline (Figures S1 and S2).
In the basal-only insulin subgroup, the rate of severe
hypoglycaemia in patients treated with liraglutide (1.2 episodes per
100 patient-years of observation [PYO]) was substantially lower than
in those who received placebo (2.6 episodes per 100 PYO, rate ratio:
0.44, 95% confidence interval [CI]: 0.28; 0.70) (Figure S3) despite bet-
ter glycaemic control. No significant differences were detected in the
rates of severe hypoglycaemia in the other insulin subgroup (rate
ratio: 1.54, 95% CI: 0.74; 3.20) and the no-insulin subgroup (rate ratio:
0.76, 95% CI: 0.47;1.21) (Figure S3). Two patients (one patient in the
basal-only insulin subgroup, randomized to placebo, and one patient
in the other insulin subgroup, randomized to liraglutide) experienced a
total of 66 severe hypoglycaemic episodes during the trial.7 A sensi-
tivity analysis excluding patients with >10 severe hypoglycaemic epi-
sodes (therefore, with just these two patients removed) confirmed a
significant reduction in the rate of severe hypoglycaemia in patients
treated with liraglutide in the basal-only subgroup (rate ratio: 0.62,
95% CI: 0.41; 0.94), and indicated comparable rates of severe
hypoglycaemia in patients treated with liraglutide and placebo in the
other insulin subgroup (rate ratio: 1.12, 95% CI: 0.56; 2.21).
At baseline, the mean ± standard deviation (SD) total daily dose of
insulin in the basal-only subgroup was 43.7 ± 35.6 IU, and in the other
insulin group was 77.1 ± 55.5 IU (Table S1). Insulin requirements during
the trial were lower in the liraglutide-treatment group than in the
placebo-treatment group. Among patients not treated with insulin at
baseline, initiation of insulin during the trial was less frequent in those ran-
domized to liraglutide than in those randomized to placebo (800/2630
[30%] vs. 1198/2541 [47%] patients, hazard ratio: 0.55, 95% CI: 0.50;
0.60) (Figure S4). Among patients treated with insulin at baseline, those in
the liraglutide group discontinued insulin during the trial more frequently
than those in the placebo group (206/2038 [10%] vs. 122/2131 [6%]
patients, hazard ratio: 1.62, 95% CI: 1.16; 2.27) (Figure S5). The number
of patients needed to be treated with liraglutide to prevent insulin
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initiation during the trial in one patient was six. The number of patients
needed to be treated with liraglutide to subsequently discontinue insulin
treatment during the trial (patients treated with insulin at baseline) in one
patient was 27. In patients treated with basal insulin, intensification (addi-
tion of fast-acting insulin or change to premixed insulin) was less fre-
quently required during the trial in the liraglutide-treatment group than in
the placebo group (Figure S6).
Compared with patients who received placebo, change in mean
insulin dose from baseline to month 36 (total dose for all types of
insulin, including prandial insulin added in the basal-only subgroup)
was significantly lower in liraglutide-treated patients in both the
basal-only insulin (estimated liraglutide vs. placebo difference:
−12.1 IU, 95% CI: −14.3; −9.9) and other insulin (estimated differ-
ence: −9.5 IU, 95% CI: −13.4;−5.6) subgroups (Table S1). A similar
result was observed with weight-corrected insulin dose (Table S1).
In addition to improvements in glycaemic control and decreased
insulin requirements, there were also significant reductions in body
weight in patients on insulin treated with liraglutide compared with
placebo, which was greater than in patients not treated with insulin at
baseline (P-interaction < .001) (Table 2).
In the main trial population, treatment with liraglutide was associated
with improvements in systolic blood pressure7 and LDL-C compared
with placebo (Table 2). Similar results were observed for systolic blood
pressure in the three subgroups by insulin use (Table 2). There was also a
trend for improvement in LDL-C in the three subgroups (Table 2).
There was a higher incidence of MACE in the subgroup of patients
treated with insulin at baseline (15%-16% of patients) than in patients
in the no-insulin subgroup (13% of patients) (Figure 2).
CV risk reductions with liraglutide compared with placebo were
shown in the main trial population, and hazard ratios were of similar
magnitude in the basal-only, any-insulin (pooled subgroup of insulin
users) and no-insulin subgroups (Figure 2). In a sensitivity analysis for
the subgroup using no insulin at baseline, liraglutide was shown to
reduce the risk of first MACE compared with placebo in patients who
were not treated with insulin at baseline and who were censored if
initiating insulin before MACE (Figure 2). The risk of MACE with
liraglutide versus placebo appeared to be unaffected by baseline insu-
lin dose (<30, 30 to <50, ≥50 IU): no interactions between randomized
treatment and these subgroups were identified (Figure 2).
4 | DISCUSSION
In this post hoc analysis of the LEADER trial, we present long-term
safety and efficacy data for GLP-1RA and insulin combination
TABLE 1 Baseline characteristics of patients according to baseline insulin use
Characteristic All patients (n = 9340)
Insulin use at baseline
Basal-only insulin (n = 3159) Other insulin (n = 1010) No insulin (n = 5171)
Male sex 6003 (64.3) 1953 (61.8) 623 (61.7) 3427 (66.3)
Age, y 64.3 ± 7.2 64.4 ± 7.2 64.8 ± 7.1 64.1 ± 7.3
Diabetes duration, y 12.8 ± 8.0 14.9 ± 7.8 16.9 ± 8.1 10.8 ± 7.4
HbA1c, % 8.7 ± 1.5 8.9 ± 1.6 8.8 ± 1.5 8.5 ± 1.5
HbA1c, mmol/mol 71.5 ± 16.7 73.8 ± 17.2 72.9 ± 16.7 69.9 ± 16.2
BMI, kg/m2 32.5 ± 6.3 32.5 ± 6.2 34.2 ± 6.6 32.2 ± 6.2
Body weight, kg 91.7 ± 21.0 91.2 ± 20.6 96.7 ± 21.3 91.1 ± 21.0
Systolic blood pressure, mm Hg 135.9 ± 17.7 136.2 ± 18.4 136.1 ± 18.1 135.7 ± 17.3
Diastolic blood pressure, mm Hg 77.1 ± 10.2 76.5 ± 10.3 74.7 ± 10.3 77.9 ± 10.1
LDL-C, mmol/L 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 2.4 ± 1.0
HDL-C, mmol/L 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
Heart failurea 1305 (14.0) 431 (13.6) 153 (15.1) 721 (13.9)
Established CVD (age ≥50 y) 7598 (81.3) 2613 (82.7) 866 (85.7) 4119 (79.7)
CVD risk factors (age ≥60 y) 1742 (18.7) 546 (17.3) 144 (14.3) 1052 (20.3)
Renal function
Normal (eGFR ≥90) 3275 (35.1) 1055 (33.4) 285 (28.2) 1935 (37.4)
Mild impairment (eGFR 60-89) 3907 (41.8) 1278 (40.5) 398 (39.4) 2231 (43.1)
Moderate impairment (eGFR 30-59) 1934 (20.7) 726 (23.0) 292 (28.9) 916 (17.7)
Severe impairment (eGFR <30) 224 (2.4) 100 (3.2) 35 (3.5) 89 (1.7)
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; NYHA, New York Heart Association. Data are mean ± standard deviation or number of patients
(proportion, %).
aChronic heart failure, NYHA class II-III.
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therapy. We have shown that addition of liraglutide to insulin treat-
ment in patients with type 2 diabetes at high CV risk improves
glycaemic control, and reduces body weight and insulin need for at
least 36 months with no increased risk of severe hypoglycaemia. We
have also shown that the CV safety of liraglutide is maintained,
irrespective of insulin use or dose at baseline. Together, these results
support the safety and efficacy of combined liraglutide and insulin
treatment.
In the largest subgroup of patients who were treated with basal-
only insulin at baseline, liraglutide compared with placebo improved
glycaemic control, reduced body weight and insulin requirement, and
halved the risk of severe hypoglycaemia, with hazard ratios for MACE
that were similar to patients not on insulin at baseline. These results
over 3 years are in agreement with and extend the findings from pre-
vious clinical trials of 6-12 months' duration with liraglutide added to
insulin.4-6,11,12 In the LIRA ADD2BASAL trial, adding liraglutide to
basal insulin for 26 weeks improved glycaemic control, body weight,
systolic blood pressure and LDL-C, and reduced insulin requirements
compared with placebo.4 In contrast to the present analysis, a higher
rate of confirmed hypoglycaemia was reported when adding
liraglutide compared with placebo to basal insulin in that trial, but the
authors suggested that this may have resulted from a lack of insulin
dose adjustment at the time of liraglutide initiation.4 A recent sub-
group analysis of the DEVOTE trial showed a reduced risk of MACE in
patients using liraglutide in combination with basal insulin compared
with patients using basal insulin without liraglutide, over a median
follow-up of 2 years.13 Adding further support to our results, this anal-
ysis also showed a non-significant trend for a reduced risk of severe
hypoglycaemia, and slightly lower mean bolus insulin dose in patients
with concomitant liraglutide use.13
F IGURE 1 Change in HbA1c from baseline in liraglutide and placebo-treatment groups, according to baseline insulin use: A, basal-only
insulin, B, other insulin and C, no insulin
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In addition to confirming the efficacy of liraglutide in combination
with insulin for glycaemic control and CV safety, we have shown that
liraglutide reduced the need for insulin initiation. NNTs with
liraglutide to prevent insulin initiation and to discontinue insulin dur-
ing the trial were low. When insulin was required in combination with
liraglutide, a lower mean dose was used, and for patients on a basal-
insulin regimen at baseline, intensification was less frequent and
delayed. These results corroborate previous studies indicating
improved or equivalent glycaemic control, and reduced weight and
rates of hypoglycaemia when liraglutide is added to basal insulin, com-
pared with more complex basal–bolus insulin regimens.5,6
While different study designs and patient populations limit direct
comparisons, the overall consistency of results between our analysis
and previous studies suggests that the established efficacy and safety
profile of liraglutide added to basal insulin is maintained in the long
term. Our results are also largely consistent with those derived from
shorter studies of other GLP-1RAs.3
Other than a neutral hazard ratio for MACE, and a non-significant
increase in the rate of severe hypoglycaemia compared with placebo,
similar results for liraglutide treatment were detected in the other
insulin subgroup to those observed in the basal-only insulin subgroup.
The hypoglycaemia result is probably related in part to the heteroge-
neous nature of the ‘other insulin’ group, but also to an ‘outlier’
patient with numerous severe hypoglycaemic episodes (when this
patient was excluded, there was no difference between the treatment
groups).
Weight reduction was greater with liraglutide compared with pla-
cebo in patients treated with insulin at baseline than in those not
requiring insulin at baseline. This is in keeping with previous studies
that have reported greater weight loss with liraglutide in insulin-
treated patients, possibly because of reversal of insulin-induced
weight gain associated with insulin dose reduction.14,15
At baseline, compared with patients not receiving insulin, insulin-
treated patients had a longer duration of diagnosed type 2 diabetes,
slightly worse glycaemic control, and higher frequency of CV disease
and renal impairment. These characteristics are consistent with a
more advanced disease state and contraindications for oral agents, as
expected for patients requiring insulin. It might be expected that beta
cell loss associated with longer diabetes duration would dictate that
insulin becomes the optimal therapy. However, we have shown that,
independent of insulin treatment and diabetes duration, liraglutide
improved glycaemic control in a similar way. Negative results of some
earlier CV outcome trials conducted before the GLP-1RA/sodium-
TABLE 2 Liraglutide effects on metabolic parameters according to baseline insulin use
Estimated treatment group difference (liraglutide vs. placebo) at 36 months
(95% CI), P-value
Estimated treatment group ratio
(liraglutide vs. placebo) at
36 months, (95% CI), P-value
Insulin use at baseline HbA1c, % Body weight, kg Systolic blood pressure, mm Hg LDL-C, mmol/L
All patients (n = 9340) −0.40 (−0.45; −0.34),
P < .001
−2.3 (−2.5; −2.0),
P < .001
−1.2 (−1.9; −0.5), P = .001 0.98 (0.96; 0.99), P = .003
Basal-only insulin (n = 3159) −0.48 (−0.57; −0.39),
P < .001
−2.5 (−2.9; −2.1),
P < .001
−1.2 (−2.4; 0.0), P = .055 0.98 (0.95; 1.01), P = .118
Other insulin (n = 1010) −0.37 (−0.54; −0.21),
P < .001
−3.5 (−4.2; −2.8),
P < .001
−1.8 (−4.0; 0.4), P = .106 0.97 (0.92; 1.01), P = .166
No insulin (n = 5171) −0.36 (−0.43; −0.29),
P < .001
−1.9 (−2.3; −1.6),
P < .001
−1.1 (−2.1; −0.2), P = .018 0.98 (0.96; 1.00), P = .029
Abbreviation: LDL-C, low-density lipoprotein cholesterol. Estimated mean differences using a mixed model for repeated measurements with a compound
symmetry variance, with treatment, sex and region as fixed effects and with age as a covariate.
F IGURE 2 Risk of first major adverse cardiovascular event with
liraglutide versus placebo, according to subgroups by insulin use. IU,
international unit; MACE, major adverse cardiovascular events; N,
number of patients analyzed. *Patients not treated with insulin at
baseline, censored if initiating insulin before MACE. †P-value for
interaction between randomized treatment and any insulin/no-insulin
subgroups. Time to first MACE with liraglutide versus placebo
analyzed using a Cox proportional-hazards model with treatment as a
covariate
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glucose co-transporter-2 inhibitor (SGLT-2i) era (e.g. VADT) have
been attributed to recruitment of a population sample with CV dis-
ease too advanced to benefit.16,17 The present analysis of LEADER
shows that the efficacy and safety profile of liraglutide is maintained
even in a type 2 diabetes population with advanced disease and at
high risk of CV events. The CV safety of liraglutide versus placebo
was confirmed for all subgroups of insulin use and dose analyzed. This
pattern of results was consistent with the prespecified subgroup ana-
lyses published previously (i.e. point estimates for hazard ratios indi-
cating reductions in MACE for the majority of subgroups).7 We have
extended the prespecified subgroup analysis for MACE by insulin use
at baseline (yes/no) with additional endpoints and more detailed
subgroups.
The interpretation of results from the analyses we present is con-
strained by limitations inherent to post hoc analyses, as well as the
limitations that apply to the primary analysis of the LEADER trial,
including recruitment of a patient population with type 2 diabetes at
high risk of CV events, limiting extrapolation of the results to patients
with less advanced type 2 diabetes.7 Nevertheless, the double-blind
nature of the trial and high patient retention rates with little missing
data increase the validity of our results. A specific limitation is the use
of subgroup analyses based on insulin treatment at baseline. Insulin
treatment was initiated, adjusted and discontinued during the trial for
some patients – according to the study design to achieve so-called
glycaemic equipoise – such that comparator treatment groups are not
equivalent to previous smaller studies specifically designed to assess
the effect of GLP-1RAs in combination with insulin. Based on the dif-
ferences in HbA1c between treatment groups in LEADER, it could be
argued that the differences in insulin use during the trial should have
been even greater. We cannot rule out the confounding effects of
these changes on our results, but defining subgroups based on insulin
use at baseline did avoid the post-randomization confounding that
could have occurred by comparing patients in the placebo and
liraglutide groups who initiated insulin during the trial (with the latter
more likely having more advanced disease). Furthermore, it is reassuring
that, compared with placebo, the effect of liraglutide on MACE was
similar in the subgroup using no insulin at baseline and in a sensitivity
analysis of patients not treated with insulin either at baseline or during
the trial. Our decision to base analyses primarily on three subgroups by
insulin use means that the no-insulin and other insulin subgroups in
particular probably represent heterogeneous cohorts of patients receiv-
ing a range of different glucose-lowering therapies. However, we rea-
soned that clear differences would probably be apparent between
patients using insulin and those using other therapies, and between
patients using basal-only insulin and those using other insulin regimens.
While we cannot infer any results for patients using specific thera-
pies within the three subgroups, more detailed subgroups would
have further reduced patient numbers and hindered interpretation. It
must also be considered that, while patients enrolled in the trial had
poor glycaemic control, intensification of therapy with GLP-1RAs
and DPP-4is in the placebo group was prohibited, and SGLT-2is
were largely unavailable during the trial. It could therefore be argued
that, for many patients in the placebo group, insulin was the only
treatment option, and that greater insulin use in this group was a
function of the trial design. Finally, our analyses based on insulin
dose are somewhat limited by a lack of available dose data for a
small proportion of patients (185 patients [4% of insulin users] at
baseline).
In summary, addition of liraglutide to insulin treatment for patients
with type 2 diabetes at high CV risk improved glycaemic control,
reduced body weight and insulin need for at least 36 months with no
increased risk of severe hypoglycaemia, and maintained CV safety.
These results support the use of combined liraglutide and insulin
treatment.
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